IT1290801B1 - Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili - Google Patents

Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili

Info

Publication number
IT1290801B1
IT1290801B1 IT96RM000479A ITRM960479A IT1290801B1 IT 1290801 B1 IT1290801 B1 IT 1290801B1 IT 96RM000479 A IT96RM000479 A IT 96RM000479A IT RM960479 A ITRM960479 A IT RM960479A IT 1290801 B1 IT1290801 B1 IT 1290801B1
Authority
IT
Italy
Prior art keywords
carnitine
pct
date jan
acceptable salts
pharmacologically acceptable
Prior art date
Application number
IT96RM000479A
Other languages
English (en)
Inventor
Simone Claudio De
Original Assignee
Mendes Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11404324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IT1290801(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mendes Srl filed Critical Mendes Srl
Priority to IT96RM000479A priority Critical patent/IT1290801B1/it
Publication of ITRM960479A0 publication Critical patent/ITRM960479A0/it
Priority to PT97922035T priority patent/PT909171E/pt
Priority to KR10-1998-0710960A priority patent/KR100479669B1/ko
Priority to AT97922035T priority patent/ATE273701T1/de
Priority to US09/147,465 priority patent/US6037373A/en
Priority to JP10505011A priority patent/JP2000514437A/ja
Priority to CA002260145A priority patent/CA2260145C/en
Priority to EP97922035A priority patent/EP0909171B1/en
Priority to DE69730330T priority patent/DE69730330T2/de
Priority to ES97922035T priority patent/ES2225968T3/es
Priority to PCT/IT1997/000113 priority patent/WO1998001128A1/en
Publication of ITRM960479A1 publication Critical patent/ITRM960479A1/it
Publication of IT1290801B1 publication Critical patent/IT1290801B1/it
Application granted granted Critical
Priority to US09/510,669 priority patent/US6380252B1/en
Priority to US09/510,672 priority patent/US6166077A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
IT96RM000479A 1996-07-05 1996-07-05 Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili IT1290801B1 (it)

Priority Applications (13)

Application Number Priority Date Filing Date Title
IT96RM000479A IT1290801B1 (it) 1996-07-05 1996-07-05 Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili
PCT/IT1997/000113 WO1998001128A1 (en) 1996-07-05 1997-05-15 Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1
JP10505011A JP2000514437A (ja) 1996-07-05 1997-05-15 Ｉｇｆ―１レベルを増加させるためのｌ―アセチルカルニチン、ｌ―イソバレリルカルニチン、ｌ―プロピオニルカルニチンの使用
DE69730330T DE69730330T2 (de) 1996-07-05 1997-05-15 Verwendung von l-acetylcarnitin, l-isovalerylcarnitin oder l-propionyl-carnitin zur steigerung des igf-spiegels
AT97922035T ATE273701T1 (de) 1996-07-05 1997-05-15 Verwendung von l-acetylcarnitin, l- isovalerylcarnitin oder l-propionyl-carnitin zur steigerung des igf-spiegels
US09/147,465 US6037373A (en) 1996-07-05 1997-05-15 Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine for increasing the levels of IGF-1
PT97922035T PT909171E (pt) 1996-07-05 1997-05-15 Utilizacao de l-acetilcarnitina, de l-isovalerilcarnitina, de l-propionilcarnitina para aumentar os niveis do igf-1
CA002260145A CA2260145C (en) 1996-07-05 1997-05-15 Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1
EP97922035A EP0909171B1 (en) 1996-07-05 1997-05-15 Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1
KR10-1998-0710960A KR100479669B1 (ko) 1996-07-05 1997-05-15 Igf-1의레벨증가에유용한l-아세틸카르니틴,l-이소발레릴카르니틴,l-프로피오닐카르니틴의용도
ES97922035T ES2225968T3 (es) 1996-07-05 1997-05-15 Uso de l-acetilcarnitina, l-isovalerilcarnitina y l-propionilcarnitina para incrementar los niveles de igf-1.
US09/510,672 US6166077A (en) 1996-07-05 2000-02-22 Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine for increasing the levels of IGF-1
US09/510,669 US6380252B1 (en) 1996-07-05 2000-02-22 Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine for increasing the levels of IGF-1

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT96RM000479A IT1290801B1 (it) 1996-07-05 1996-07-05 Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili

Publications (3)

Publication Number Publication Date
ITRM960479A0 ITRM960479A0 (it) 1996-07-05
ITRM960479A1 ITRM960479A1 (it) 1998-01-05
IT1290801B1 true IT1290801B1 (it) 1998-12-11

Family

ID=11404324

Family Applications (1)

Application Number Title Priority Date Filing Date
IT96RM000479A IT1290801B1 (it) 1996-07-05 1996-07-05 Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili

Country Status (11)

Country Link
US (2) US6037373A (it)
EP (1) EP0909171B1 (it)
JP (1) JP2000514437A (it)
KR (1) KR100479669B1 (it)
AT (1) ATE273701T1 (it)
CA (1) CA2260145C (it)
DE (1) DE69730330T2 (it)
ES (1) ES2225968T3 (it)
IT (1) IT1290801B1 (it)
PT (1) PT909171E (it)
WO (1) WO1998001128A1 (it)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380252B1 (en) * 1996-07-05 2002-04-30 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine for increasing the levels of IGF-1
IT1290801B1 (it) * 1996-07-05 1998-12-11 Mendes Srl Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili
DE19718826A1 (de) * 1997-05-05 1998-11-12 Marion S Dr Eckmiller Verwendung biologisch aktiver Wirkstoffe zum Beeinflussen des Extrazellulär-Raumes von Sinneszellen und Verfahren zur Wirkstoff-Administrationssteuerung
IT1306178B1 (it) 1999-07-27 2001-05-30 Sigma Tau Ind Farmaceuti Uso della l-carnitina e dei suoi alcanoil derivati per la preparazionedi un medicamento utile nel trattamento del paziente affetto da
IT1316990B1 (it) * 2000-02-17 2003-05-26 Sigma Tau Ind Farmaceuti Metodo per aumentare l'espressione genica per geni trasfettati.
US20010025027A1 (en) * 2000-03-07 2001-09-27 Sonis Stephen T. Inhibition of ceramide for the prevention and treatment of oral mucositis induced by antineoplastic drugs or radiation
IT1317938B1 (it) * 2000-11-17 2003-07-15 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di alterazioni delmetabolismo lipidico, delle forme allergiche e per attivare le difese
IT1317937B1 (it) * 2000-11-17 2003-07-15 Sigma Tau Healthscience Spa Composizione per stimolare le difese immunitarie ed il metabolismo delferro comprendente una alcanoil l-carnitina e lattoferrina.
IT1317079B1 (it) * 2000-12-21 2003-05-26 Sigma Tau Ind Farmaceuti Uso della isovaleril l-carnitina per la preparazione di un medicamentoper la prevenzione e cura dell'osteoporosi.
ITRM20010708A1 (it) * 2001-12-04 2003-06-04 Sigma Tau Ind Farmaceuti Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile.
US6652891B2 (en) 2001-12-12 2003-11-25 Herbasway Laboratories, Llc Co-enzyme Q10 dietary supplement
CA2369810C (en) * 2002-01-30 2007-08-07 1474791 Ontario Limited Method of treating pain
US20050106183A1 (en) * 2002-01-31 2005-05-19 Lamb Gregory B. Method of treating pain
US7407778B2 (en) 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) * 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
US7026312B2 (en) 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
ITRM20020492A1 (it) * 2002-10-01 2004-04-02 Sigma Tau Ind Farmaceuti Uso della propionil l-carnitina per la preparazione di un medicamento per il trattamento del glaucoma.
ITRM20020620A1 (it) 2002-12-13 2004-06-14 Sigma Tau Ind Farmaceuti Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.
US7776913B2 (en) * 2002-12-13 2010-08-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Carnitines for treating or preventing disorders caused by andropause
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
ATE437884T1 (de) * 2003-05-29 2009-08-15 Jay W Pettegrew Glycerophosphocholin und derivate davon zur medizinischen abbildung von neuropsychiatrischen erkrankungen
US8173618B2 (en) * 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
CA2598792A1 (en) 2005-03-02 2006-09-08 Metanomics Gmbh Process for the production of fine chemicals
JP2006347935A (ja) * 2005-06-15 2006-12-28 Masanori Ogata 炎症性サイトカインの産生が関与する疾患の予防及び／又は治療のための医薬
US20070087975A1 (en) * 2005-10-17 2007-04-19 Sigma-Tau Industrie Farmaceutiche Riunite Spa Compound useful for the prevention and treatment of left ventricular hypertrophy in dialysed patients
US7957213B2 (en) * 2006-02-09 2011-06-07 Hynix Semiconductor, Inc. Semiconductor memory apparatus
KR100738959B1 (ko) 2006-02-09 2007-07-12 주식회사 하이닉스반도체 반도체 메모리 장치의 센스 앰프 전원 공급 회로 및 방법
KR20090071598A (ko) 2006-09-18 2009-07-01 랩터 파마슈티컬 인코포레이티드 수용체 결합 단백질(ｒａｐ)-접합체 투여에 의한 간 질환의 치료
WO2008113862A2 (en) * 2007-03-21 2008-09-25 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance
EP2155769B1 (en) 2007-05-04 2012-06-27 Katholieke Universiteit Leuven KU Leuven Research & Development Tissue degeneration protection
BRPI0812306A2 (pt) * 2007-05-24 2014-11-25 Sigma Tau Ind Farmaceuti Composição útil para a prevenção do efeito adverso devido ao uso de agonistas ppar-gama
US8597640B2 (en) * 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1245699B (it) * 1991-05-29 1994-10-14 Sigma Tau Ind Farmaceuti Derivati della l-carnitina quali agenti terapeutici per il trattamento delle miopatie, della degenarazione neuronale e per inibire la proteolisi
US5240961A (en) * 1992-07-02 1993-08-31 Shug Austin L Method of treating reduced insulin-like growth factor and bone loss associated with aging
WO1995000137A1 (de) * 1993-06-21 1995-01-05 Bernardini, Attilio Verwendung von acylcarnitin zur behandlund von aids-krankheiten
IT1290801B1 (it) * 1996-07-05 1998-12-11 Mendes Srl Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili

Also Published As

Publication number Publication date
ES2225968T3 (es) 2005-03-16
ITRM960479A1 (it) 1998-01-05
US6037373A (en) 2000-03-14
KR20000022515A (ko) 2000-04-25
EP0909171B1 (en) 2004-08-18
CA2260145A1 (en) 1998-01-15
PT909171E (pt) 2004-11-30
CA2260145C (en) 2007-01-09
ITRM960479A0 (it) 1996-07-05
DE69730330D1 (de) 2004-09-23
KR100479669B1 (ko) 2005-06-13
DE69730330T2 (de) 2005-02-10
JP2000514437A (ja) 2000-10-31
US6166077A (en) 2000-12-26
EP0909171A1 (en) 1999-04-21
ATE273701T1 (de) 2004-09-15
WO1998001128A1 (en) 1998-01-15

Similar Documents

Publication Publication Date Title
IT1290801B1 (it) Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili
EP0865258B1 (en) Telescopic bone plate for use in bone lengthening by distraction osteogenesis
Conway et al. Plastic surgery for closure of decubitus ulcers in patients with paraplegia: based on experience with 1,000 cases
Kerstens et al. Temporomandibular joint symptoms in orthognathic surgery
Inoue et al. Corrective ulnar osteotomy for malunited anterior Monteggia lesions in children: 12 patients followed for 1-12 years
UA84665C2 (ru) Способ ингибирования опосредствованного ангиогенеза в ткани у пациента с неоваскулярным заболеванием роговицы
WO1999051262A3 (en) Use of igfi for treating articular cartilage disorders
EA200400881A1 (ru) Азаарилпиперазины
Rajgopal et al. Temporomandibular ankylosis: a report of 15 cases
Jones et al. Vertebrobasilar artery insufficiency in rheumatoid atlantoaxial subluxation.
ATE217197T1 (de) Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa
DE69515038D1 (de) Verwendung von raloxifen und dessen analogen zur herstellung eines medikaments zur behandlung viraler erkrankungen
BR0214075A (pt) Dosagem unitária que compreende um análogo de prostaglandina para tratar constipação
OHTANI et al. Anterior surgical decompression for thoracic myelopathy as a result of ossification of the posterior longitudinal ligament.
WO2001089537A3 (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
MD970254A (en) Use of melatonine for treatment of patients having a medicamental dependence
Hollander et al. Using an esterified hyaluronan fleece to promote healing in difficult-to-treat wounds
Janovec Short humerus: results of 11 prolongations in 10 children and adolescents
DE69223455D1 (de) WS7622A enthaltende prophylaktische/therapeutische Zusammensetzung zur Vorbeugung und Behandlung von verstreuter, intravaskulärer Koagulation, chronischer, infektiöser Atemwegskrankheiten oder chronischer Bronchitis
Cantore et al. Tabetic lumbar osteoarthropathy with cauda equina syndrome
Baldini et al. Femoral nerve palsy secondary to anticoagulant therapy
Ha et al. The Simple Excision of Ossicles for Osgood-Schlatter Lesion
DK0769945T3 (da) Brug af 2-phenyl-3-aroylbenzothiophenderivater til fremstilling af et medikament til behandling af knogler og knoglebrud
PADOVANI et al. The treatment of spasticity by means of dorsal longitudinal myelotomy and lozenge-shaped griseotomy
RU1774861C (ru) Способ лечени болевого синдрома при обострении хронического радикулита

Legal Events

Date Code Title Description
0001 Granted